Correlation Between Arcus Biosciences and Virpax Pharmaceuticals
Can any of the company-specific risk be diversified away by investing in both Arcus Biosciences and Virpax Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Arcus Biosciences and Virpax Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Arcus Biosciences and Virpax Pharmaceuticals, you can compare the effects of market volatilities on Arcus Biosciences and Virpax Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Arcus Biosciences with a short position of Virpax Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Arcus Biosciences and Virpax Pharmaceuticals.
Diversification Opportunities for Arcus Biosciences and Virpax Pharmaceuticals
-0.23 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Arcus and Virpax is -0.23. Overlapping area represents the amount of risk that can be diversified away by holding Arcus Biosciences and Virpax Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Virpax Pharmaceuticals and Arcus Biosciences is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Arcus Biosciences are associated (or correlated) with Virpax Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Virpax Pharmaceuticals has no effect on the direction of Arcus Biosciences i.e., Arcus Biosciences and Virpax Pharmaceuticals go up and down completely randomly.
Pair Corralation between Arcus Biosciences and Virpax Pharmaceuticals
Given the investment horizon of 90 days Arcus Biosciences is expected to generate 0.41 times more return on investment than Virpax Pharmaceuticals. However, Arcus Biosciences is 2.41 times less risky than Virpax Pharmaceuticals. It trades about 0.04 of its potential returns per unit of risk. Virpax Pharmaceuticals is currently generating about -0.09 per unit of risk. If you would invest 1,527 in Arcus Biosciences on September 25, 2024 and sell it today you would earn a total of 64.00 from holding Arcus Biosciences or generate 4.19% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Against |
Strength | Insignificant |
Accuracy | 100.0% |
Values | Daily Returns |
Arcus Biosciences vs. Virpax Pharmaceuticals
Performance |
Timeline |
Arcus Biosciences |
Virpax Pharmaceuticals |
Arcus Biosciences and Virpax Pharmaceuticals Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Arcus Biosciences and Virpax Pharmaceuticals
The main advantage of trading using opposite Arcus Biosciences and Virpax Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Arcus Biosciences position performs unexpectedly, Virpax Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Virpax Pharmaceuticals will offset losses from the drop in Virpax Pharmaceuticals' long position.Arcus Biosciences vs. Fate Therapeutics | Arcus Biosciences vs. Caribou Biosciences | Arcus Biosciences vs. Karyopharm Therapeutics | Arcus Biosciences vs. X4 Pharmaceuticals |
Virpax Pharmaceuticals vs. Fate Therapeutics | Virpax Pharmaceuticals vs. Caribou Biosciences | Virpax Pharmaceuticals vs. Karyopharm Therapeutics | Virpax Pharmaceuticals vs. X4 Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Complementary Tools
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |